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Exome Sequencing Identifies Truncating Mutations
in Human SERPINF1 in Autosomal-Recessive
Osteogenesis Imperfecta
Jutta Becker,1,11 Oliver Semler,2,11 Christian Gilissen,3,11 Yun Li,1,4 Hanno Jo¨rn Bolz,1,5 Cecilia Giunta,6
Carsten Bergmann,5,7 Marianne Rohrbach,6 Friederike Koerber,8 Katharina Zimmermann,1
Petra de Vries,3 Brunhilde Wirth,1,4,9 Eckhard Schoenau,2 Bernd Wollnik,1,4,10 Joris A. Veltman,3
Alexander Hoischen,3 and Christian Netzer1,*
Osteogenesis imperfecta (OI) is a heterogeneous genetic disorder characterized by bone fragility and susceptibility to fractures after
minimal trauma. After mutations in all known OI genes had been excluded by Sanger sequencing, we applied next-generation
sequencing to analyze the exome of a single individual who has a severe form of the disease and whose parents are second cousins.
A total of 26,922 variations from the human reference genome sequence were subjected to several filtering steps. In addition, we ex-
tracted the genotypes of all dbSNP130-annotated SNPs from the exome sequencing data and used these 299,494 genotypes as markers
for the genome-wide identification of homozygous regions. A single homozygous truncating mutation, affecting SERPINF1 on chromo-
some 17p13.3, that was embedded into a homozygous stretch of 2.99 Mb remained. The mutation was also homozygous in the affected
brother of the index patient. Subsequently, we identified homozygosity for two different truncating SERPINF1 mutations in two unre-
lated patients with OI and parental consanguinity. All four individuals with SERPINF1mutations have severe OI. Fractures of long bones
and severe vertebral compression fractures with resulting deformities were observed as early as the first year of life in these individuals.
Collagen analyses with cultured dermal fibroblasts displayed no evidence for impaired collagen folding, posttranslational modification,
or secretion. SERPINF1 encodes pigment epithelium-derived factor (PEDF), a secreted glycoprotein of the serpin superfamily. PEDF is
a multifunctional protein and one of the strongest inhibitors of angiogenesis currently known in humans. Our data provide genetic
evidence for PEDF involvement in human bone homeostasis.Osteogenesis imperfecta (OI; MIM 166200, 166210,
610854, 259420, 166220, 610967, 610968, 610682,
610915, and 259440 for type I to IX of the disease) is
a genetic disorder characterized by bone fragility and
susceptibility to fractures after minimal trauma. Disease
severity ranges from very mild forms without fractures to
intrauterine fractures and perinatal lethality.1,2 Typical ex-
traskeletal manifestations, which affect a variable number
of OI patients, are dentinogenesis imperfecta, hearing loss,
and blue sclera. Most individuals with OI have autosomal-
dominantly inherited mutations in COL1A1 (MIM
120150) or COL1A2 (MIM 120160), the two genes that
encode the a chains of the major bone matrix protein
collagen type 1. Mutations in these genes result in quanti-
tative and/or qualitative defects in type 1 collagen produc-
tion by osteoblasts.3–6
In a minority of OI patients, the disorder is inherited in
an autosomal-recessive manner. Recently, mutations in
six different genes have been associated with these OI
forms. CRTAP (MIM 605497), LEPRE1 (MIM 610339),
and PPIB (MIM 123841) encode components of the prolyl
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among other functions, modifies the Pro986 residue of
the type 1 collagen a1 chains.12,15 SERPINH1 (MIM
600943) and FKBP10 (MIM 607063) encode collagen
chaperones.16–20 HSP47, the gene product of SERPINH1,
may monitor the final integrity of the triple helix that is
formed out of two a1 chains and one a2 chain.17 SP7 or
OSX (MIM 606633) encodes a transcription factor that,
based on the function of its murine homolog, is assumed
to regulate the differentiation of preosteoblasts to osteo-
blasts.21,22 In a substantial number of COL1A1 and
COL1A2 mutation-negative OI cases, the underlying
molecular defect is unknown.17
The current standard therapy for moderate and severe
forms of OI (types II, III, and IV in the Sillence classifica-
tion23) is cyclic intravenous application of bisphopho-
nates.1 These compounds are synthetic pyrophosphate
analogs that deposit on the bone surface, where they
inhibit osteoclasts.24,25 Bisphosphonate treatment, ideally
starting in early childhood, increases bonemineral density.
There is evidence that it also reduces fracture rates, chronic
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Here, we report the identification of a gene that is
mutated in a severe form of OI. The gene was identified
in an affected male individual who has a similarly affected
older brother. The parents come from the United Arab
Emirates and are second cousins, suggesting autosomal-
recessive inheritance of the disease. Mutations in all genes
known to cause autosomal-dominant and -recessive OI
(see above) had been excluded by direct Sanger sequencing
of genomic DNA. We therefore decided to follow
a genome-wide sequencing approach to identify the cause
of the disease in this patient. The study was approved by
the Medical Ethics Committee of the Radboud University
Nijmegen Medical Centre. Written informed consent to
participate in the study and to publish clinical data and
radiographs was obtained for the index patient and for
all other OI patients described in this paper.
We sequenced the exome (~18,600 genes) of the index
patient by using the SureSelect human exome kit (Agilent,
Santa Clara, CA, USA) and one-quarter of a SOLiD 4 system
sequencing slide (Life Technologies, Carlsbad, CA, USA).
We obtained 3.7 Gb of mappable sequence data. Color
space reads were mapped to the hg18 reference genome
with the SOLiD bioscope software version 1.2, which
utilizes an iterative mapping approach. In total, 71% of
bases came from the targeted exome, resulting in a mean
coverage of 65-fold (Table S1, available online). Single
nucleotide variants were subsequently called by the Di-
Bayes algorithm with high call stringency. Ninety-two
percent of the targeted exons were covered more than
ten times. Small insertions and deletions were detected
with the SOLiD Small InDel Tool. Called SNP variants
and indels were then combined and annotated with
a custom analysis pipeline.
Initial quality filtering (>5 variant reads and >15%
variant reads) resulted in the identification of 13,487
genetic variants, including 6,298 nonsynonymous
changes, in the coding regions or the canonical dinucleo-
tides of the splice sites (Table S2). We applied a prioritiza-
tion scheme to identify the pathogenic mutation, similar
to what was done in recent studies.27–29 For a recessive
disease, it is possible that pathogenic mutations are listed
as benign polymorphisms in dbSNP or in our internal
variant database because individuals without the respec-
tive phenotype can be heterozygous carriers. However,
given the rare incidence of autosomal-recessive OI, we
considered such a scenario to be unlikely. We therefore
excluded known dbSNP130 variants as well as variants
from our in-house variant database, reducing the number
of candidates by more than 98% to a total of 318 variants.
For further analysis, we applied an autosomal-recessive
disease model and assumed that the causal mutation was
inherited from a common ancestor because of parental
consanguinity. Under this assumption, only 17 autosomal
candidate genes with homozygous variants in the index
patient remained. To prioritize these candidate genes, we
developed an algorithm for unbiased identification of
homozygous regions in the genome: we extracted theThe Amerigenotypes of all dbSNP130-annotated autosomal SNPs
that had a read coverage of at least 15-fold from the exome
sequencing data of the index patient. This resulted in
a total of 299,494 genotypes, which increased the number
of potential geneticmarkers for the identification of homo-
zygous regions in the genome more than 17-fold. Variants
displaying an identical SNP allele in R95% of all reads
were considered to be homozygous, SNPs with 30%–70%
variation reads were considered to be heterozygous, and
SNPs with <30% or with 70%–95% variation reads were
considered ambiguous. A genomic region was identified
as a homozygous stretch if at least 500 consecutive SNP
markers were called as homozygous; there was a maximum
tolerance of two heterozygous SNPs per 500 markers (to
account for possible sequencing or mapping errors). In
the dataset of the index patient, this algorithm identified
seven homozygous regions on chromosomes 1, 6, 11,
and 17 (Table S3 and Figure S1). Only three of the 17
homozygous variants in the index patient’s exome were
located in one of these homozygous regions: two missense
variants on chromosome 1 (p.Gln361Arg [c.1082A>G] in
LPHN2 [RefSeq accession number NM_012302.2] and
p.Thr1799Met [c.5396C>T] in INADL [MIM 603199;
NM_176877.2]) and a stop mutation (p.Tyr232X
[c.696C>G]) affecting SERPINF1 (MIM 172860;
NM_002615.4) on chromosome 17p13.3 (Table S4). The
stop mutation was embedded into a homozygous stretch
spanning 2.99 Mb (Figure 1D).
We regarded SERPINF1 as the best candidate for further
evaluation. Validation by Sanger sequencing confirmed
that the c.696C>G (p.Tyr232X) mutation was indeed
present in a homozygous state in the index patient (Fig-
ure 1C). We also tested DNA samples of the patient’s
parents, his affected brother (patient 2), and his two
healthy sisters. Only the affected brother carried the muta-
tion in a homozygous state, whereas both parents and
both sisters were heterozygous carriers, compatible with
autosomal-recessive inheritance of the disorder in the
family (Figure S2A). The mutation was not detected on
460 control chromosomes from individuals with the
same regional ancestry as the index patient. These results
confirmed that the identified mutation is not a rare poly-
morphism in the United Arab Emirates population. No
other SERPINF1 nonsense variant was observed in more
than 120 in-house exomes, indicating the rare nature of
loss-of-function mutations in this gene.
As a next step, we performed Sanger sequencing of all
seven coding SERPINF1 exons on genomic DNA samples
obtained from two unrelated Turkish patients (patients 3
and 4), an Iraqi patient, and an Italian patient, all clinically
diagnosed with OI. These four patients had no detectable
COL1A1 or COL1A2 mutations. The Italian patient had
moderate OI (type IV in the Sillence classification23),
whereas the other patients suffered from a severe form of
OI, comparable to the course of the disease in the Arabian
index family. Only the Turkish patients were born to
consanguineous parents. In these two patients, wecan Journal of Human Genetics 88, 362–371, March 11, 2011 363
Figure 1. Identification of a Homozygous Mutation in SERPINF1 by Exome Sequencing
(A) Overview of SERPINF1 coverage by exome sequencing. Upper: An ideogram illustrating the SERPINF1 location in the chromosomal
band 17p13.3 (red bar). Middle: The genomic structure and localization of SERPINF1 in more detail. Lower: The per-base coverage, with
an axis to the right ranging from 0 to 275-fold coverage.
(B) Detailed view of individual sequencing reads overlapping the stop mutation in exon 6. All 18 reads at the genomic position
g.1,625,154 (hg18) display the homozygous stop mutation c.696C>G.
(C) Validation of the SERPINF1mutation in exon 6 by Sanger sequencing of genomic DNA. Electropherograms of a control individual, of
the index patient, and of his father are shown. The position of the mutation is marked with an arrow. The affected codon is framed in
black. The control individual carries the wild-type sequence (wt) in both copies of the gene. The patient’s father is a heterozygous carrier
of the mutation (genotype wt/mut). The patient is homozygous for the c.696C>G mutation (mut/mut).
(D) Upper: Contains an ideogram of the p-arm of chromosome 17 illustrating the localization of SERPINF1. Lower : The homozygous
regions on chromosome 17 at the genomic positions g.97,058-3,091,589 and g.3,299,188-4,983,922 are recognizable. Each dot repre-
sents one of the SNP markers that were included in the analysis. SNPs within a region that was called as homozygous are colored in
purple. The position along the y axis indicates the ratio of the number of reads with the nonreference allele to the total number of reads;
the value is 1.0 if only reference or nonreference reads are present at a given SNP position (y axis, ratio of variant reads/all reads per SNP
position; x axis, genomic position along the p-arm of chromosome 17).identified truncating SERPINF1 mutations: patient 3 was
homozygous for the insertion c.324_325dupCT (p.Tyr109-
SerfsX5) in exon 4, resulting in a frameshift with a prema-
ture stop codon (Figure 2 and Figure S3A). Patient 4 carried
the homozygous stop mutation c.1132C>T (p.Gln378X)
in exon 8 (Figure 2 and Figure S3B). The patients’ parents364 The American Journal of Human Genetics 88, 362–371, March 1(as obligate carriers) and two healthy sisters of patient 3
were heterozygous for the respective mutation (Figures
S2B and S2C). The insertion mutation c.324_325dupCT
was excluded in 460 Turkish control chromosomes, and
the stop mutation c.1132C>T was not present on 272
Turkish control alleles, demonstrating that neither of these1, 2011
p.Tyr232Xp.Tyr109SerfsX5 p.Gln378X
Signal peptide Reactive center loop
Glycosylation site, Asn285
Phosphorylation sites, Ser24/114/227
Negatively charged residues 
involved in collagen binding
c.696C>G c.1132C>Tc.324_325dupCT
PEDF
SERPINF1 cDNA structure
Exon   2 3 4 5 6 7 8
Figure 2. SERPINF1 and PEDF Scheme
Schematic representation of pigment
epithelium-derived factor (PEDF,
NP_002606) and of the coding exons of
the SERPINF1 cDNA (NM_002615.4). The
locations of the exons are aligned relative
to the regions of the PEDF each exon
encodes. The positions of the three trun-
cating mutations identified in OI patients
are indicated by arrows. Several important
protein domains described in the literature
are depicted.36two sequence changes is a rare polymorphism. The Iraqi
and the Italian patient were negative for mutations in
the coding region of SERPINF1.
SERPINF1 encodes pigment-epithelium-derived factor
(PEDF), a 50 kDa secreted glycoprotein of the serpin super-
family. The p.Tyr232X and p.Tyr109SerfsX5mutations can
be predicted to cause null alleles because of nonsense-
mediated mRNA decay (NMD). We found experimental
evidence for NMD of the mutated transcript in peripheral
blood by direct sequencing of a PCR-amplified cDNA frag-
ment encompassing the frameshift mutation p.Tyr109-
SerfsX5 (Figure S4). In the father of patient 3, the cDNA
sequence of the mutated allele was only detectable as
a faint background signal behind the wild-type sequence,
whereas Sanger sequencing on genomic DNA derived
from this obligate mutation carrier displayed equally
strong signals for the mutated and the wild-type allele.
This observation suggests that the number of mutated
transcripts serving as templates for the preceding RT-PCR
reaction is strongly reduced in comparison to the number
of transcripts with the wild-type sequence. The c.1132C>T
(p.Gln378X) mutation is located in the last coding exon of
SERPINF1, 123 bp upstream of the regular stop codon
(Figure 2). The corresponding transcript should therefore
escape the NMD machinery.30 However, the C terminus
of PEDF (amino acids 384–415) represents one of the
four highly conserved regions of the protein.31 Extensive
mutagenesis studies with cDNA expression vectors of
human PEDF revealed that any deletion of the C terminus,
which encompasses more than the four C-terminal amino
acids (amino acids 415–418), abolishes secretion of the
protein by transiently transfected mammalian cells.32
Moreover, the premature stop codon identified in patient
3 resides within the reactive center loop (RCL) of PEDFThe American Journal of Human G(Figure 2). An in vitro deletion of
a segment of the RCL (Pro373–
Ala380) as well as substitutions of
Gly376 and Leu377 by alanine re-
sulted in abrogation of PEDF secre-
tion, suggesting that the RCL is
important for the interaction of
PEDF with the secretory apparatus.32
The p.Gln378X mutation therefore
most likely represents a functionalnull allele. This interpretation is supported by the observa-
tion that the phenotypic consequences of the p.Gln378X
mutation are indistinguishable from those of the
p.Tyr232X and p.Tyr109SerfsX5 mutations (see below).
The four affected children with SERPINF1 mutations
(referred to as patients 1–4) exhibited similar clinical symp-
toms and disease severity, currently classified as OI type III.
There were no intrauterine fractures reported, and birth
length and weight were normal. Dentinogenesis imper-
fecta was not present. Formal hearing tests were not per-
formed, but there were no clinical signs of hearing impair-
ment. The sclerae were grayish. No ophthalmological
problems were seen. The serum levels showed moderately
elevated levels for alkaline phosphatase and procollagen-
1-C-peptide and moderately increased values for the osteo-
clast marker deoxypyridinoline (Table 1). Compared to
other OI patients, these biochemical findings are not
uncommon and can also be found in patients with
COL1A1 or COL1A2 mutations. All four patients had frac-
tures of long bones and severe vertebral compression frac-
tures, and resulting deformities were seen as early as in
their first year of life. Some of the fractured bones required
surgical corrections of deformities and insertions of tele-
scopic rods. Figures 3 and 4 show a selection of radiographs
of patients 3 and 4. The radiological findings were typical
for patients with severe forms of OI. There were no distinc-
tive radiological abnormalities that would allow a further
diagnostic subclassification. In Figure S5, we present
whole-body DXA scans taken of patients 2–4 during their
last bone-mineral-density measurement. These DXA scans
give an impression of the degree of skeletal deformity.
In all patients, bone mineral density was severely
reduced. All four patients developed short stature during
early childhood and were wheelchair bound. Threeenetics 88, 362–371, March 11, 2011 365
Table 1. Clinical Features of Patients with Recessive OI and
Mutations in SERPINF1
Findings Patient 1 Patient 2 Patient 3 Patient 4
OI typea III III III III
Age at first visit
(years)
1 8/12 11 4/12 6/12 1 1/12
Age at last visit
(years)
3 2/12 16 3/12 8 7/12 5 11/12
Age at start of
bisphosphonate
treatment
1 8/12 11 4/12 7/12 1 1/12
Birth length
and birth
weight
normal normal normal normal
Confirmed
prenatal fractures
no no no no
Age at first
fracture (months)
4 unknown 6 6
Color of sclera grayish grayish grayish grayish
Dentinogenesis
imperfecta
no no no no
Hypermobility
of joints
no no no no
Hearing
impairment
no no no no
Old fractures
of extremitiesb
yes yes yes yes
Vertebral
fracturesb
multiple multiple multiple multiple
Bowing of upper
extremitiesb
moderate severe mild moderate
Bowing of lower
extremitiesb
severe severe moderate moderate
Shortening of
upper extremitiesb
moderate severe mild mild
Shortening of
lower extremitiesb
moderate severe moderate mild
Weight at first
visit kg/BMI (SD)
9/0.5 40/þ3.2 7.5/1.4 11.9/þ1.8
Weight at last
visit kg/BMI (SD)
9.9/1.1 45/þ3.5 17/1.4 14/1.5
Length at first
visit cm/(SD)
not done 98/8.8 67/0.2 78.3/0.7
Length at last
visit cm/(SD)
76/5.6 101/10.2 110/3.8 101.5/2.8
Retarded gross
motor functions
yes yes yes yes
Mobility at first
visit (BAMFc)
2 1 0 4
Mobility at last
visit (BAMFc)
4 2 6 6
Intelligence normal normal normal normal
Calcium levelb normal normal normal normal
Alkaline
phosphatase at
first visit [U/l]
353 283 295 348
Table 1. Continued
Findings Patient 1 Patient 2 Patient 3 Patient 4
Alkaline
phosphatase
at last visit [U/l]
328 154 269 344
Procollagen-1-C-
peptide (marker
for osteoblastic
activity) [mg/l]b
720 430 200 375
Deoxypyridinoline/
creatinine (marker
for osteoclastic
activity) [nM/mM]
at first visit
not done 86.5 118.9 not done
Deoxypyridinoline/
creatinine (marker
for osteoclastic
activity) [nM/mM]
at last visit
64.9 60.1 63.1 65.3
First available
bone density,
DXA whole-body
measurement (Z
score)
6.1
(lumbar
spine)
3.7 2.7 2.0
a According to the Sillence classification.23
b At first presentation.
c Brief assessment of motor function.60
366 The American Journal of Human Genetics 88, 362–371, March 1patients had received early medical treatment and physio-
therapeutic training and were able to stand with assistance
or to walk a few steps with assistive devices. The fourth
patient, who was 11 years old at first presentation and
severely adipose with a BMI of 44.1 kg/m2, was completely
immobile and dependent on external support for all activ-
ities of daily life. The clinical findings are summarized in
Table 1. There were no hints of an involvement of other
organ systems, and abdominal ultrasound scans gave
normal results. All patients had received a cyclic intrave-
nous bisphosphonate treatment with the compound ner-
idronate prior to this study, according to the Italian regime
for children with OI.33 Upon treatment, there was verte-
bral reshaping and an increase in vertebral height, an
observation that has been reported previously by several
OI investigators.1 As an example of treatment outcome,
the changes of vertebral size during treatment of patient
3 are presented in Figure S6. This assumed therapeutic
effect was similar in all four patients. The parents of the
patients, all heterozygous carriers of the disease-causing
mutations, were healthy and had no overt signs of reduced
bone mineral density and no history of previous fractures.
DXA measurements have not been performed in the
parents.
To analyze the effect of PEDF-truncating mutations on
posttranslational modification of collagens, we performed
a standard biochemical analysis of type I, III, and V colla-
gens extracted from cultured dermal fibroblasts of patient
3.34 SDS-PAGE showed normal migration of collagens
(Figure S7), which suggests that altered posttranslational
modification of collagens is unlikely to play a role in the1, 2011
Figure 3. Radiological Features of
Patient 3
(A and B) Thorax and pelvis of patient 3 at
the age of 6 months showing no signs of
rip or clavicular fractures, only a slightly
decreased vertebral height, a small pelvis
and moderately delayed development of
the hips.
(C and D) Radiographs of the right and left
leg when the patient was 1.6 years old
show severe bowing of both femurs,
multiple old and new fractures, and a pseu-
darthrosis in the right femur. In the
epiphysis, lines resulting from intravenous
bisphosphonate treatment are visible. The
tibiae display no severe deformities.disease pathogenesis. Abnormal type I collagen migration
in SDS-PAGE analyses can be observed in autosomal-reces-
sive OI caused by CRTAP, LEPRE1, and PPIB mutations, as
well as in most patients with autosomal-dominant OI re-
sulting from COL1A1 or COL1A2 mutations.2,9,10,13,14 In
order to investigate whether the secretion of triple helical
collagen type I was impaired, pulse-chase experiments
were performed. As shown in Figure S8, collagen secretion
in fibroblasts of patient 3 was normal. However, subtle
impairments of type I collagen secretion might remain
unrecognized with this experimental design and therefore
cannot be excluded. Delayed collagen secretion has been
observed in fibroblasts from OI patients with LEPRE1, SER-
PINH1, and FKBP10 mutations, and it is also a frequent
effect of COL1A1 or COL1A2 glycine substitutions impair-
ing triple helix formation.10,16,17,35
The human genome encodes 36 serpin proteins, most of
which are protease inhibitors.36 On the basis of the
sequence similarities of the proteins and exon-intron orga-
nization of the genes, serpins have been organized into 16
clades. PEDF falls into the F1 clade. HSP47, which has been
associated with autosomal-recessive OI in humans and in
dachshunds, is categorized as clade H1 (and thus encoded
by SERPINH1).17,18 The closest homologs of PEDF are
alpha-2 antiplasmin (encoded by SERPINF2 [MIM
613168]) and complement component 1 inhibitor (en-
coded by SERPING1[ MIM 606860]).37 Unlike these two
proteins, PEDF and HSP47 are not thought to exhibit
protease inhibitory activity.38,39 PEDF contains two
conserved regions with significant homology to other
serpins.31 One of these regions is the C terminus (amino
acids 384–415). Among 16 human serpins with strong
sequence similarities to the PEDF C terminus, HSP47The American Journal of Human Gdisplays the greatest homology (47%
sequence identity and 88% sequence
homology).31
PEDF was initially isolated from
conditioned medium of fetal human
retinal pigment epithelium cells and
characterized as a factor that can
induce the differentiation of retino-blastoma cells into cells with several characteristics of
normal neurons.40–42 With the discovery that the protein
is one of the strongest inhibitors of angiogenesis in hu-
mans known to date, utilizing this property for therapeutic
applications became a main focus of PEDF research.43,44
PEDF is thought to counteract the effect of vascular endo-
thelial growth factor (VEGF).45,46 VEGF-A is the molecular
target for the neutralizing humanized antibody bevacizu-
mab (Avastatin, FDA-approved for the treatment of certain
types of malignant tumors) and its fragment ranibizumab
(Lucentis, a FDA-approved medication for wet macular
degeneration).47 Consequently, the first clinical FDA trials
with PEDF are dedicated to the treatment of the wet form
of age-related macular dengeneration as an ocular disease
resulting from choroidal neovascularization. These clinical
trials with intravitreal administration of virally delivered
PEDF are currently in Phase II.46,48,49 In a mouse model
of ischemia-induced retinal angiogenesis, systemically
administered purified PEDF was able to completely elimi-
nate aberrant neovascularization.50
There is a growing list of other cellular functions of PEDF,
including immunomodulation, protection against oxida-
tive stress, and expansion of the neural stem cell niche.36,51
The underlying molecular mechanisms have only been
partially elucidated. PEDF is expressed in a wide range of
fetal and adult tissues, including bonemarrow, lung, brain,
liver, and eye.52 An intracellular function, for example as
a chaperone, has not been reported so far. As a secreted
protein, PEDF accumulates in the extracellular matrix and
binds, among others, to collagen type I.53,54
It is somewhat unexpected that loss of PEDF leads to
severe OI in humans because the murine knockout model
has no overt bone phenotype but exhibits vascular andenetics 88, 362–371, March 11, 2011 367
Figure 4. Radiological Features of
Patient 4
(A) Hand radiogram at the age of 6 years
shows no signs of fractures or skeletal
dysplasia and only a mild delay of bone
age.
(B) The right arm at the age of 5.4 years
shows severe deformities of the humerus
with multiple old fractures and callus
formation in the diaphysis.
(C) Left hemithorax at the age of 4.3 years
displays no deformities or fractures of rips.
(D) Right leg at the age of 2.9 years after
surgical rodding with an intramedullar
telescopic rod because of a fracture.
(E) Fractured right leg 3 months earlier.
Also visible are the epiphyseal lines result-
ing from cyclic intravenous bisphospho-
nate treatment.
(F) Left leg with a fracture after minimal
trauma at the age of 2.2 years.
(G) Left leg a few weeks later after surgical
treatment with an intramedullar tele-
scopic rod.epithelial abnormalities. Serpinf1/mice lacking exons3–6
of the gene are viable and fertile and display increased mi-
crovessel density in the retina, kidney, pancreas, and pros-
tate. On gross examination, the pancreas appeared
enlarged. At 3 months of age, the mice developed prostatic
hyperplasia.55However, impaired organ functionswerenot
reported, as is also the case in ourOI patientswith SERPINF1
mutations. Clarifying whether the OI phenotype is indeed
restricted to humans with loss of PEDF will require detailed
analyses of bone homeostasis and bone mineral density in
Serpinf1/ mice. Of note, experimental data demon-
strating absence of mRNA and protein expression have
not been provided with the original publication.55 There-
fore, it remains possible that, e.g., splicing between Serpinf1
exon 2 and exon 7 is able to produce a form of the protein
with a residual function that is essential to bone.368 The American Journal of Human Genetics 88, 362–371, March 11, 2011Expression analyses performed
with bone tissue from wild-type
mice as well as recent in vitro experi-
ments with murine cell systems
strongly support a function of PEDF
in bone formation and remodeling.
PEDF is expressed in osteoblasts,
chondrocytes, and,to a lesser extent,
osteoclasts. The protein was detected
in areas of active bone remodeling.
In growing mouse bone, strong posi-
tive immunostaining for PEDF was
observed predominantly in the bone
matrix of the trabeculae of the
primary spongiosa and the perios-
teum; adjacent osteoblasts displayed
only faint staining.56,57 PEDF is also
expressed in avascular layers of the
epiphyseal growth plate, as opposedto the expression pattern of VEGF, which is found in vascu-
larized layers.56,58 Cell-culture experiments provided
evidence that PEDF inhibits osteoclast differentiation and
hence bone resorption via osteoprotegerin (OPG) and
RANKL (receptor activator of NF-kB ligand) in a dose-
dependent manner.59 This inhibitory effect was confirmed
in vivo with a mouse model system for inflammatory bone
destruction. Receptor activator of NF-kB (RANK), its ligand
RANKL, and the decoy receptor OPG are central regulators
of osteoclast development and function.
In light of these data and our collagen studies with
patient fibroblasts, it is intriguing to speculate that the
OI phenotype observed in patients with SERPINF1 muta-
tions is the result of a pathomechanism that is primarily
independent of alterations in type I collagen synthesis or
intracellular processing. The published immunostaining
pattern is consistent with a scenario in which PEDF is
rapidly secreted by osteoblasts and subsequently binds to
the newly laid type I collagen in the extracellular matrix.56
The balance between PEDF and VEGF expression in
regions of active bone formation is thought to regulate
neovascularisation at these sites, a process that is necessary
for the provision of osteoblast and osteoclast precursor
cells.45,57 Loss of PEDF could disturb this balance. As
a result, there could be an excess of osteoclast precursor
cells in areas of active bone remodeling and at the epiphy-
seal plate. In the absence of PEDF secretion by osteoblasts,
osteoclast precursor cells could differentiate into osteo-
clasts without restraints, leading to excessive bone resorp-
tion. Dissecting the pathomechanism of this OI form will
require further studies.
In conclusion, we report the identification of pathogenic
germlinemutations in human SERPINF1. The fact that four
patients who have the uniform diagnosis of OI type III and
descend from consanguineous families from two popula-
tions are homozygous for three different truncating
SERPINF1mutations establishes loss of PEDF as the molec-
ular cause of the observed phenotype. The power of exome
sequencing in combination with homozygosity analysis as
a strategy for unraveling the cause of autosomal-recessive
disorders in consanguineous families is highlighted by
the fact that finding themutatedgene requiredonly a single
affected individual. Because we identifiedmutations in two
out of four additionalCOL1A1- andCOL1A2-negative fami-
lies, there might be a substantial number of other auto-
somal-recessively inherited OI cases caused by SERPINF1
mutations. The data presented here provide in vivo
evidence for an involvement of PEDF in human bone
homeostasis. This well-characterized protein could be
a promising candidate for the development of a drug for
the treatment of OI patients with inborn loss of PEDF and
possibly also for the treatment of other low bone-mass
phenotypes. Deciphering themolecular pathway that leads
to reduced bonemineral density in patients with SERPINF1
mutations might unveil additional targets for therapeutic
interventions in this severe form of OI.Supplemental Data
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